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Abstract
The progranulin gene (PGRN) encodes a pleiotropic molecule with anti-inflammatory actions and neuronal
protective effects. Accordingly, PGRN-deficient mice have been demonstrated to develop enhanced inflammation
and progressive neurodegeneration. Loss of function mutations of the PGRN gene have been also reported to
cause frontotemporal lobar degeneration (FTLD), a neurodegenerative disease leading to dementia generally in the
presenium. Since neurodegeneration might be negatively impacted by chronic inflammation, the possible
influence of PGRN defects on inflammatory pathways appears to be of great relevance for the understanding of
neurodegeneration pathogenic processes in those patients. However, no data about the inflammatory profile of
PGRN-defective subjects have been so far provided.
In this study, we analyzed serum levels of the pro-inflammatory mediators IL-6, TNF-a and IL-18 in FTLD patients with or
without PGRN mutations, at both pre-symptomatic and symptomatic stages. We provide evidence that circulating IL-6
is increased in PGRN-mutated FTLD patients, as compared to both PGRN non-mutated FTLD patients and controls. In
contrast, levels of IL-6 were not altered in asymptomatic subjects carrying the PGRN mutations. Finally, TNF-a and IL-18
serum levels did not differ among all groups of included subjects.
We conclude that the profile of circulating pro-inflammatory cytokines is altered in PGRN-related symptomatic FTLD.
Thus, our findings point to IL-6 as a possible specific mediator and a potential therapeutic target in this monogenic
disease, suggesting that an enhanced inflammatory response might be indeed involved in its progression.
Introduction
Progranulin (PGRN), also known as granulin-epithelin
precursor, is a pleiotropic molecule promoting survival,
cell cycle progression, proliferation, and migration of sev-
eral cell types, and is recognized as an important regulator
of the wound-healing response [1,2]. In the periphery,
PGRN is involved in inflammation regulation and, as a
whole molecule, it possesses anti-inflammatory effects
[3,4]. Within the brain, PGRN is up-regulated in neuroin-
flammatory conditions and its increased expression by
microglia may be relevant in responses to brain injury,
neuroinflammation and neurodegeneration [5,6]. PGRN is
e n c o d e db yas i n g l eg e n eo nc h r o m o s o m e1 7 q 2 1a n d ,
interestingly, loss of-function mutations in the PGRN gene
have been identified as a monogenic cause of frontotem-
poral lobar degeneration (FTLD) [7-9]. Up to now, almost
70 pathogenic PGRN mutations have been described, and
all are expected to cause PGRN haploinsufficiency (Alzhei-
mer Disease and Frontotemporal Dementia Database.
http://www.molgen.ua.ac.be/FTDmutations/). Patients
with PGRN mutations may present with initial disease
symptoms typically in their 50s or 60s, with a wide spec-
trum of disease onset and clinical presentation [10].
The heterogeneity of PGRN-related FTLD suggests that
several other factors of both genetic and environmental
nature, including inflammation, can influence disease
expression. Indeed, similar to other neurodegenerative
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the pathophysiology of FTLD, since the disease is charac-
terized by in vivo activation of microglia [11], and
increased levels of intrathecal pro-inflammatory mediators
[12,13]. However, no data in FTLD patients establishing a
link between PGRN mutations and inflammatory changes
have been so far provided, and demonstration of an imbal-
ance in inflammation pathways and establishment of the
timing of inflammation abnormalities in PGRN-related
disease might be of crucial help in identifying new thera-
peutic targets for this orphan disorder.
In the present study, we evaluated FTLD patients with
and without PGRN haploinsufficiency for circulating levels
of cytokines with pro-inflammatory action that are likely
relevant to neurodegeneration, epitomized by IL-6, TNF-a
and IL-18. In particular, IL-6 and TNF-a, which are mea-
surable in human serum, were chosen here as inflamma-
tory markers because of their implication in the animal
model of PGRN deficiency-mediated neurodegeneration
[14]. In addition, the cytokine IL-18 was also included in
this study because of its pivotal role in neuroinflammation
and its association with cognitive decline in demented
patients with Alzheimer’s disease [15]. Finally, asympto-
matic PGRN mutation carriers were evaluated to assess
the inflammatory cytokine profile in pre-symptomatic
disease stages.
Materials and methods
Patients were recruited who met clinical criteria for
FTLD [16,17]. All subjects underwent a somatic and neu-
rological evaluation, routine laboratory tests, a brain
structural imaging study, and blood sampling for genetic
screening and serum PGRN dosage. The diagnostic
assessment was accomplished by a review of full medical
history, a semi-structured neurological examination, and
a complete standardized neuropsychological status eva-
luation. Inclusion and exclusion criteria were applied as
previously reported [18].
A group of healthy controls (HC) were further
included. They were neither related to one another nor
to FTLD patients; in particular, we selected only sub-
jects in the same patients’ age range, with a MMSE
score ≥26 and a formal neurological examination that
excluded the presence of a dementing condition.
Moreover, siblings belonging to families of FTLD
patients bearing PGRN mutations were considered. Cog-
nitive or behavioral deficits were excluded by a standar-
dized neuropsychological assessment. These were
subgrouped into asymptomatic subjects carrying PGRN
mutation (ASYMP-PGRN+), to assess inflammatory pro-
files before PGRN-related FTLD onset, and those with-
out PGRN mutations (ASYMP-PGRN-). A control group
similar in age composition was recruited as well.
The study was performed with the understanding and
written consent of each subject, and was reviewed and
approved by the local ethical committee.
Venous blood samples were drawn from each patient
for PGRN sequencing. Total genomic DNA was prepared
from peripheral blood according to standard procedures,
as previously published [9]. All the 12 exons plus exon 0
of PGRN and at least 30 base pairs (bp) of their flanking
introns were sequenced. Serum PGRN was assessed by
enzyme-linked immunosorbent assay (ELISA) kit (Adipo-
Gen Inc), according to the manufacturer’s instructions.
Similarly, IL-6 and TNF-a were measured using specific
high-sensitivity ELISA kits (Quantikine HS, R&DSys-
tems), while IL-18 was determined using antibodies
(coating: clone 125-2H; detecting: clone 159-12B) and
standards from MBL (Nagoya, Japan). The limit of detec-
tion for these assays was 0.16 pg/ml for IL-6; 0.5 pg/ml
for TNF-a and 15 pg/ml for IL-18. Comparisons among
the subject groups on continuous variables were per-
formed using univariate analyses of variance. Correlations
between cytokine serum levels and demographic or clini-
cal characteristics were performed by using correlation
analyses (Pearson’sr )a n dF i s h e r ’s r to z transformation.
The level of statistical significance was set at P < 0.05.
Results
Serum cytokine levels in FTLD patients and control
subjects
Ninety-two FTLD patients, namely 78 without PGRN
mutations (i.e. FTLD PGRN-) and 14 carrying PGRN
mutations (FTLD PGRN+; g.1977_1980delCACT, n = 13
and g.2473C > T, n = 1) along with 59 healthy age-
matched controls were included in the present study.
The socio-demographic, clinical and biochemical data
about the FTLD patients and the age-matched control
subjects are summarized in T a b l e1 .C y t o k i n el e v e l s
were analyzed in serum of all subjects and expressed as
mean pg/ml ± SEM.
As reported in Figure 1, in FTLD PGRN+, serum IL-6
levels were significantly increased (4.95 ± 1.61) as com-
pared to FTLD PGRN- (2.74 ± 0.31, P <0 . 0 0 1 )a n dH C
(2.00 ± 0.20, P = 0.009).
TNF-a did not significantly differ in FTLD PGRN+
(1.33 ± 0.79) as compared to FTLD PGRN- (3.17 ± 5.80,
P = 0.656) and HC (2.14 ± 1.54, P = 0.201).
Comparably, no differences in IL-18 levels were
observed in FTLD PGRN+ (443.7 ± 168.6), than FTLD
PGRN- (414.2 ± 139.1, P = 0.582) and HC (433.3 ± 178.9,
P = 0.848).
There were no significant correlations between levels of
the three cytokines analyzed and cognitive impairment,
as measured by Clinical Dementia Rating for Frontotem-
poral Dementia and Mini-Mental State Examination, in
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(data not shown).
Serum cytokine levels in asymptomatic patients with
PGRN mutations and control subjects
In order to verify whether increased levels of IL-6
detected in FTLD with PGRN mutations were present
before the development of the disease, we analyzed 11
ASYMP PGRN+ (g.1977_1980delCACT). At the time of
recruitment, these subjects belonged to the second gen-
eration of nuclear families, in which the case indexes
showed a mean disease onset at 63.3 ± 2.3 years. Based
on these demographic data, we are allowed to consider
that ASYMP PGRN+ subjects, with a mean age of 42.9
± 4.6 years, were enrolled in a period of their life almost
20 years before the estimated onset of symptoms.
Eighteen young healthy subject controls and 14 ASYMP
PGRN- young asymptomatic controls with no patho-
genic PGRN mutations were included in the study as
well. Demographic characteristics of the 3 groups are
shown in Table 2.
Different from what was observed in patients with
symptomatic FTLD carrying PGRN mutations, the levels
of IL-6 in patients who had not yet developed the dis-
ease were not higher than those of age-matched con-
trols. There were no significant differences between
ASYMP PGRN+ (1.03 ± 0.73) and ASYMP PGRN- (1.53
± 2.06, P = 0.465) or age-matched young controls (1.51
± 1.88, P = 0.459). These data suggest that IL-6 systemic
dysregulation in FTLD subjects with PGRN loss may be
associated with disease development.
Similar negative results were also obtained for the
other two cytokines, i.e. TNF-a and IL-18.
Discussion
Recent studies on PGRN-deficient mice suggest that
endogenous PGRN plays a central role in the regulation
of inflammatory cytokine production. In particular,
PGRN deficiency causes progressive neurodegeneration
through enhanced microglia activation and chronic
inflammation characterized by increased production of
pro-inflammatory molecules, such as IL-6 and TNF-a
[14,19,20]. Indeed, the pleiotropic pro-inflammatory
cytokines IL-6 and TNF-a have been proposed to exert
both protective and detrimental effects in CNS, but
their neurotoxic capability might prevail in chronic con-
ditions [21,22]. In accord with animal data, the main
results of our study indicate that the pro-inflammatory
cytokine IL-6 is significantly elevated in FTLD PGRN+
patients, as a consequence of both the loss of functional
PGRN and the development of dementia. In the same
direction, a previous study has shown that polymorph-
isms in the IL-6 gene can modify cognitive and beha-
vioral performances in FTLD patients [23], supporting
the potential specific role of this cytokine in influencing
symptom occurrence in FTLD. However, in our sample
Table 1 Characteristics of subjects included in the study
Healthy controls FTLD
FTLD PGRN- FTD PGRN+
Total number 59 78 14
Gender (female), % 57 44 60
Age, years 65.2 ± 1.0 65.5 ± 0.8 63.3 ± 2.3
Diagnosis, bvFTD/PPA, % - 75.6/24.4 71.4/28.6
MMSE, score 29.1 ± 0.13 21.3 ± 0.8* 18.5 ± 3.0*
Progranulin, ng/ml n.a. 179.7 ± 6.6 63.4 ± 9.2**
FTLD: frontotemporal lobar degeneration; PGRN-: no progranulin pathogenetic mutations; PGRN+: progranulin pathogenetic mutations.
Results are expressed as mean ± SEM (standard error), or otherwise specified. n.a.: not available.
* P < 0.0001, significantly different from healthy control subjects.
** P < 0.0001, significantly different from FTLD.
Figure 1 Serum IL-6 levels in FTLD patients and control
subjects. IL-6 levels in FTLD patients carrying (FTLD PGRN+, black
bar) and not carrying (FTLD PGRN-, grey bar) progranulin mutations
and age-matched healthy controls (HC, open bar). Results are
reported as histograms representing IL-6 pg/ml mean values with
SEM error bars.
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there was no correlation between serum levels of IL-6
and MMSE scores, suggesting that the relationship
between peripheral cytokine elevation and cognitive
impairment might be more complex than the associa-
tion of cytokine gene variants with the disease.
D i f f e r e n tf r o mI L - 6 ,i no u rs t u d yT N F - a tends, with-
out reaching statistical significance, to be higher in
FTLD patients without PGRN mutations, as compared
to controls. Indeed, another study reported that in
FTLD patients versus controls, cerebrospinal fluid levels
of TNF-a were significantly increased, without statisti-
cally significant changes in circulating TNF-a [13].
T h u s ,i tc a n n o tb ee x c l u d e dt h a tT N F - a might play a
role in FTLD, likely independent upon PGRN haploin-
sufficiency, but this needs to be further investigated.
Finally, although emerging data suggest that another
pro-inflammatory cytokine, namely IL-18, might be
associated with dementia of Alzheimer’s type [15], in
this study we did not observe any differences in IL-18
serum concentration between FTLD subjects and con-
trols, suggesting that dissimilar inflammatory mechan-
isms might be implicated in the two different types of
dementia.
Overall, these data show for the first time a direct link
between an increase in systemic inflammation and
PGRN deficiency in FTLD patients, implicating IL-6 as
a specific player in this type of FTLD-related inflamma-
tory dysregulation. More specifically, as serum IL-6 con-
centration has been demonstrated to be unchanged in
asymptomatic, preclinical stages of the disease, we can
argue that an enhanced IL-6-dependent inflammatory
response is crucial for symptom development and pro-
gression. Thus, pharmacological inhibition of inflamma-
tion, obtained for instance by treating patients with
either anti-inflammatory drugs or, ideally, with specific
cytokine inhibitors as anti-IL-6 or anti-IL-6R antibody,
should be explored as a valuable intervention to slow
neurodegeneration in PGRN-defective FTLD patients.
This work has some limitations that need to be taken
into account for discussion purposes. First of all, the
number of subjects, namely patients carrying PGRN
mutations, is low and the results should be further repli-
cated in larger samples. Moreover, it might be of inter-
est to study an extended panel of cytokines, to study
peripheral versus intrathecal cytokine modulation, and
to study ex-vivo cellular production of inflammatory
mediators and post-mortem analysis of brain tissue to
elucidate in depth the inflammatory response pathway
changes that underlay PGRN insufficiency. Finally,
although IL-6 apparently exerts a predominantly detri-
mental action in chronic brain disorders [21], the mole-
cular mechanisms determining IL-6 effects on FTLD
neurodegenerative pathways remain to be investigated.
Despite these limitations, this study demonstrates for
the first time an increased inflammatory response in
PGRN-defective humans, suggesting that inflammation
might participate in leading to the onset of FTLD symp-
toms, and highlights possible new molecular targets for
PGRN-related FTLD treatment.
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Table 2 Characteristics of asymptomatic subjects included in the study
Young healthy controls Asymptomatic subjects
ASYMP-PGRN- ASYMP-PGRN+
Total number 18 14 11
Gender (females %) 61.1 57.1 41.7
Age, years (mean ± SEM) 42.2 ± 3.1 43.7 ± 3.2 42.9 ± 4.6
MMSE, score (mean ± SEM) 29.7 ± 0.2 30 ± 0.0 29.25 ± 0.5
Progranulin, ng/ml (mean ± SEM) n.a. 204.3 ± 25.5 58.6 ± 17.4**
** P < 0.0001, significantly different from ASYMP-PGRN-.
ASYMP-PGRN-: young asymptomatic subjects with no pathogenic progranulin mutations; ASYMP-PGRN+: young asymptomatic subjects with pathogenic
progranulin mutations.
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